Barbiturates, Serum or Plasma, Quantitative

Also known as: BARBS SP

Clinical Use

Use

This test is used to optimize dosing and monitor patient adherence to barbiturate therapy. It is useful for ruling out barbiturate exposure. For follow-up testing of a presumptive result, the preferred test is Barbiturates, Urine, Quantitative (2012213).

Special Instructions

Not provided.

Limitations

The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive.

Test Details

New York Approved

Methodology

Mass Spectrometry

Biomarkers

Butalbital

Analyte

Concentration / Level

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

Pentobarbital

Analyte

Concentration / Level

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

Phenobarbital

Analyte

Concentration / Level

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

LOINC Codes

Result Codes

3948-7 - Phenobarb SerPl-mCnc
6895-7 - Butalbital SerPl-mCnc
3924-8 - Pentobarb SerPl-mCnc

Result Turnaround Time

1-7 days

Specimen

Serum

Volume

3.5 mL

Minimum Volume

1.5 mL

Container

ARUP standard transport tube

Collection Instructions

Separate serum or plasma from cells ASAP or within 2 hours of collection.

Causes for Rejection

Separator tubes. Plasma or whole blood collected in light blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.